INO stock forecast, quote, news & analysis
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases... Show more
Why Inovio Pharmaceuticals (INO) Stock Is Up +63% in the Last 30 Days
Key Takeaways
- Inovio Pharmaceuticals (INO) surged roughly 63% over the past 30 days, driven primarily by a single-session rally following a major regulatory milestone.
- The U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, the company's first commercial product, for adults with recurrent respiratory papillomatosis (RRP).
- The approval marks the first FDA-cleared plasmid DNA-based immunotherapy, a milestone that validates Inovio's broader DNA medicines platform.
- Analysts responded swiftly: H.C. Wainwright upgraded INO to Buy with a $5 price target, while Piper Sandler reiterated its Buy rating and a $4 target.
- The move followed a prolonged decline, with the stock trading near $0.60 before the approval and down substantially on a year-to-date basis.
- Execution risk remains, including the commercial launch and a required confirmatory study to verify clinical benefit.
- For additional detail, readers can review the ticker's Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see how AI-driven trading strategies are positioning across the market.
Inovio Pharmaceuticals (INO) Company Overview and Market Position
Inovio Pharmaceuticals, Inc. is a Plymouth Meeting, Pennsylvania-based biotechnology company focused on developing and commercializing DNA medicines that help treat and protect people from HPV-related diseases, cancer, and infectious diseases. The company's platform optimizes the design and delivery of DNA plasmids, which instruct the body's own cells to produce disease-fighting tools, and uses its proprietary CELLECTRA electroporation device to deliver those medicines into cells.
Inovio's lead asset, VOCERYQ (formerly INO-3107), targets recurrent respiratory papillomatosis (RRP), a rare and chronic condition caused by HPV types 6 and 11 that produces recurring wart-like growths in the airways and often requires repeated surgeries. The broader pipeline includes candidates for HPV-related cancers and other indications. Investors follow the stock for its high-risk, high-reward profile, given that the company only recently secured its first regulatory approval and is now transitioning into a commercial-stage organization.
Inovio Pharmaceuticals (INO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, INO climbed approximately 63%, from a closing price of $1.16 on October 2 to $1.89 on November 2. Nearly all of that gain was concentrated in a single session, when shares rose more than 200% after the FDA's approval of VOCERYQ was announced.
The quarterly trend was far more volatile. The stock began the period near $0.70 in early August, rallied to a peak of roughly $1.45 in early September, and then reversed into a steady downtrend that carried it to a closing low of $0.60 on October 30. The regulatory decision on VOCERYQ abruptly reversed that slide, leaving the stock sharply higher versus its late-October trough even as it remains well off its early-September peak.
What Drove INO Stock Price in the Last 30 Days
The dominant catalyst was the FDA's accelerated approval of VOCERYQ for the treatment of adults with RRP, announced after the market close on October 30. As the company's first approved product and the first plasmid DNA-based immunotherapy cleared in the United States, the decision transformed Inovio's outlook from a pre-revenue developer to a company with a commercial asset. The approval was based on clinical data showing that a portion of treated patients required no additional papilloma surgeries during a 12-month follow-up period.
The rally was amplified by analyst actions. H.C. Wainwright upgraded INO from Neutral to Buy and raised its price target to $5 from $2.50, citing peak annual VOCERYQ revenue potential of $450 million. Piper Sandler reiterated its Buy rating with a $4 target. Trading volume was exceptionally heavy, reflecting the binary nature of the regulatory event and a wave of repositioning by investors who had been positioned for continued weakness.
What Drove INO Stock Performance Over the Last Quarter
For most of the quarter, INO was defined by investor caution ahead of the FDA decision. The stock rallied in August and early September on optimism around the pipeline, then gave back those gains through September and October as uncertainty over the regulatory outcome, a thin cash position, and limited revenue weighed on sentiment. The shares fell roughly 58% from their September peak to the October 30 close.
The approval reversed that narrative in a single day. Competition in the RRP space, including Precigen's rival immunotherapy, and the requirement for a confirmatory study remain part of the broader quarterly story, but the regulatory milestone fundamentally reset how the market evaluates the company's DNA medicine platform.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a broader universe of hundreds of bots that trade thousands of tickers. Only the top-performing and most relevant strategies appear in this section, where bots are differentiated by trading style, timeframe, and performance metrics. This makes the page a useful reference for investors who want to observe how automated, data-driven systems are navigating market conditions. Readers can browse the section to compare approaches and monitor how AI-driven signals evolve alongside individual stocks and broader market trends.
INO Stock Forecast Drivers: What Investors Should Watch Next
The most immediate milestone is Inovio's third-quarter 2026 earnings report, scheduled for November 10, 2026, which should provide updated financials and guidance around the VOCERYQ launch. Investors will also monitor the commercial rollout, with the company expecting to begin shipping the therapy within roughly 60 days and to reach full field deployment in the first half of 2027.
Longer term, attention will focus on the confirmatory study required as a condition of the accelerated approval, including the draft protocol due before the end of 2026. Pricing, reimbursement, physician adoption, and competitive dynamics with existing RRP treatments will be key variables in determining whether the launch translates into sustained revenue. As with any newly commercial biotech, execution and capital management remain important risks for investors to weigh.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INO sees its Stochastic Oscillator ascending out of oversold territory
On November 02, 2026, the Stochastic Oscillator for INO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In 49 of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on INO as a result. In 54 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for INO just turned positive on November 02, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.
INO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 185 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The 10-day moving average for INO crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
INO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for INO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. INO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (44.708) is normal, around the industry mean (3.104). P/E Ratio (-1.835) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of synthetic vaccines and immune therapies for cancers and infectious diseases
Industry Biotechnology